J
Jiangsu Jiangshan Juyuan Biotechnology
Jiangsu Jland Biotech Co., Ltd produces non-animal derived collagen for cosmetics, research and medical applications
About Jiangsu Jiangshan Juyuan Biotechnology
Jiangsu Jiangshan Juyuan Biotechnology (Jland Biotech), established in 2015, operates as a specialized developer and producer of recombinant collagen, positioning itself as a key player in the biotechnology sector. The company was co-founded by the Aland Group, a global nutrition provider, in collaboration with Professor Yang Shulin's team, who invented the recombinant human collagen (RHC) technology, and the Nanjing University of Science and Technology. This strategic foundation has enabled Jland Biotech to focus on the entire value chain, from research and development to the production and application of recombinant collagen proteins. In November 2023, the company's growth trajectory was highlighted by its selection as a potential unicorn enterprise in Jiangsu Province.
Jland Biotech's business model encompasses a vertically integrated approach, covering the full industrial chain from gene design and strain construction to large-scale production and downstream application development. The company generates revenue through three primary channels: the sale of recombinant protein raw materials, providing Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM) services for cosmetic brands, and marketing its own branded products. This structure allows Jland to serve a diverse client base, including over 300 global brands and factories, such as Proya, OSM, and Hongxing Erke. A significant partnership was formed with Germany-based Evonik, which not only invested in Jland through its venture capital arm but also collaborates on marketing Jland's vegan collagen for various skincare applications.
The core of Jland Biotech's offering is its recombinant human-like collagen, branded as Biollagen™, produced via a patented fermentation process using Pichia pastoris yeast. This method creates a pure, animal-free product, addressing the growing demand for vegan and ethically sourced cosmetic ingredients. The company's product portfolio is extensive, including various types of recombinant collagen (Type I, III, IV, V, XVII), fibronectin, and elastin. These proteins are formulated into raw materials for other manufacturers or used in Jland's own finished products, such as freeze-dried repair series, active glass series, and anti-wrinkle skincare lines. A key feature is the company's advanced production capability, which can yield 20 tons of high-purity recombinant collagen powder annually, and its use of AI-driven freeze-drying technology to preserve product efficacy.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | May 2025 | $14M | $55M | SDIC Fund Management · Yuexiu Industrial Fund | ↗ |
| SERIES B✓Equity / VC | Sep 2023 | $0 | — | Evonik Venture Capital · Cenova Capital | ↗ |
Growth signals
Latest recorded traffic for Jiangsu Jiangshan Juyuan Biotechnology is 220 monthly website visits, up 1000% over the last three months. Jiangsu Jiangshan Juyuan Biotechnology's team grew 60% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Jiangsu Jiangshan Juyuan Biotechnology in its local ecosystem
The Jiangsu Jiangshan Juyuan Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Evonik Venture Capital
Cenova Capital
Series B and later2 investors entered at this stage
SDIC Fund Management- YFYuexiu Industrial Fund
Other known investors2 additional known investors
Jiangnan University
Nanjing University of Science and Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Jiangsu Jiangshan Juyuan Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Jiangsu Jiangshan Juyuan Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








